Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, efficacy, pharmacodynamics, and pharmacokinetics of SAR339375 administered as weekly subcutaneous injection in patients with sin
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Developer: GENZYME CORPORATION
- Phase: II
- Execution start: 15/10/2020
- End of execution: 31/08/2023
- IP: RAFAEL JOSE ESTEBAN DE LA ROSA